Sandostatin LAR (long‐acting octreotide acetate) for malignant carcinoid syndrome: a 3‐year experience

Alimentary Pharmacology and Therapeutics - Tập 17 Số 3 - Trang 437-444 - 2003
J. Garland1, John Buscombe1, Catherine Bouvier1, Pierre‐Marc Bouloux1, Michael H. Chapman1, A. C. Chow1, Nicola Reynolds2, Martyn Caplin1
1Neuroendocrine Tumour Clinic and
2Pharmacy, Royal Free Hospital, London, UK

Tóm tắt

SummaryBackground : Somatostatin analogues are the best therapy for controlling the symptoms of malignant carcinoid syndrome. Octreotide acetate given as subcutaneous injection up to three times daily, intramuscular Lanreotide injection given once per 1–2 weeks and monthly intramuscular Sandostatin LAR have demonstrated similar efficacy in short‐term studies.Aim : To assess the long‐term effect of Sandostatin LAR on the management of patients with malignant carcinoid syndrome.Methods : This was a 3‐year retrospective study. Twenty‐seven patients were assessed with a median follow‐up of 23 months. Thirteen patients were switched from subcutaneous octreotide and 14 patients were octreotide naive. All patients showed avid uptake on indium‐111 octreotide imaging.Results : Ten of the 13 patients previously on subcutaneous octreotide and 13 of the 14 patients who were octreotide naive had good symptom control on Sandostatin LAR. Over the period of follow‐up, many patients showed progression of their tumour and required additional therapies. Patients expressed a preference for monthly intramuscular Sandostatin LAR as opposed to daily subcutaneous injections of octreotide. Although Sandostatin LAR was difficult to administer in certain instances, overall it was well tolerated.Conclusions : Sandostatin LAR provides good long‐term symptomatic control in patients with malignant carcinoid syndrome; it is well tolerated and patients expressed improved satisfaction in their management.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(63)90951-6

10.1016/S0140-6736(98)02286-7

10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2

Hodgson HJF, 1993, Gastroenterology. Clinical Science and Practice, 643

Kaplan LM, 1991, Harrison's Principles and Practices of Internal Medicine, 1386

10.1159/000051856

10.1177/000456329703400415

10.1023/A:1008215730767

Rochaix P, 1999, Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors., 308

10.1038/bjc.1998.101

10.1159/000201211

10.1007/BF03259208

10.1159/000049160

10.1136/gut.38.3.430

10.1016/S0002-9270(99)00146-X

10.1016/0026-0495(95)90306-2

Kuhn JM, 1994, Pharmacokinetic and pharmacodynamic properties of a long acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers, Br J Clin Pharmacol, 382, 13

Larsson G, 2001, Quality of Life in Patients with Endocrine Gastrointestinal Tumours. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 989

10.1046/j.1365-2036.2000.00738.x

10.1200/JCO.1999.17.2.600

10.1530/eje.0.1460295

10.1530/eje.0.1430353

Weckbecker G, 1992, Antiproliferative effects of the somatostatin analogue octreotide (SMS 201‐995) on ZR‐75‐1 human breast cancer cells in vivo and in vitro, Cancer Res, 52, 4973

10.1172/JCI118618

10.1016/S0014-5793(96)01159-3

10.1002/jso.10062

10.1007/BF01536042

10.3109/02841869309083916

10.7326/0003-4819-110-1-35

10.3109/02841869109092409

10.1097/00001813-199601001-00004

10.1097/00006231-200001000-00016

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 17 Số 3

437-444

Thông tin tác giả